Researchers study 'ACT TIL' approach to treating metastatic melanoma
Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL). Tumor tissues were surgically removed from patients, minced and grown in culture. The treatment combined chemotherapy, then ACT with TIL, followed by interleukin-2 (IL-2). The combination therapy drew a high response rate from some patients.
The study appears in the October issue of the Journal of Immunotherapy.
"Our purpose was to demonstrate the feasibility of performing TIL growth and the efficacy of ACT TIL therapy using techniques developed at the National Cancer Institute," said Amod Sarnaik, M.D., assistant member of the Cutaneous Oncology Department at Moffitt. "Combining chemotherapy with ACT and high dose IL-2 resulted in a 38 percent objective response rate in patients with metastatic melanoma."
"Although our clinical study successfully met its goal of demonstrating that ACT TIL therapy could be offered to advanced melanoma patients, strategies to improve on its feasibility and efficacy are under way," said Shari A. Pilon-Thomas, Ph.D., assistant member of the Immunology Program at Moffitt. "Combination therapies that enhance the proliferation and function of TIL are being explored."
More information: journals.lww.com/i… er_of.4.aspx
A second-generation ACT TIL trial is enrolling patients at Moffitt. For more, patients can go to the trial website or call Moffitt at 813-745-4279.
- Tumor-Infiltrating lymphocyte grade IDs melanoma survival Jun 20, 2012 | not rated yet | 0
- Combination therapy delivers one-two punch to skin cancer, boosting anti-tumor activity Aug 16, 2012 | not rated yet | 0
- Researchers study effect of chemotherapy combined with immunotherapy for advanced cancers Oct 09, 2012 | not rated yet | 0
- Response rate high for some patients with metastatic melanoma treated with vemurafenib Mar 16, 2012 | not rated yet | 0
- Immunotherapy and chemotherapy regimen may prolong survival in advanced cancers Apr 03, 2012 | not rated yet | 0
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
The Durability of Bone: Long Falls
7 hours ago I am doing a paper on the physics in Valve's Portal and got interested in the "Long Fall Boots" that prevent any damage no matter how far you fall. I...
Is energy convertible to matter?
9 hours ago Can we convert energy to matter?
Rotating electron as a dipole is this right?
11 hours ago An electron as shown by the Stern Gerlach experiment behaves like a dipole (albeit only in one of two states). I have been trying to figure out how...
Dipole term in multipole expansion
15 hours ago Hi. I'm having some difficult in understanding something about the dipole term in a multipole expansion. Griffiths writes the expansion as a sum of...
Bubbles in a Pre-Boiling/Boiling pot of water
16 hours ago How is it that bubbles form on the bottom of a surface of a pot of boiling water? I think that there is probably an elementary answer to this...
Assumptions of Griffith's fracture theory
May 21, 2013 Any experts on Griffith's fracture theory? I am studying the subject and I am having hard time finding out if the theory is valid for all possible...
- More from Physics Forums - Classical Physics
More news stories
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
Immunology May 20, 2013 | 4.8 / 5 (22) | 8 |
(Medical Xpress)—Scientists at King's College London have discovered that Vitamin D has the potential to significantly reduce the symptoms of asthma. The study, led by Professor Catherine Hawrylowicz from ...
Immunology May 20, 2013 | 5 / 5 (1) | 0 |
Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed.
Immunology May 20, 2013 | 5 / 5 (5) | 0 |
Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells in the laboratory. The researchers showed that, in mice, ...
Immunology May 16, 2013 | 4.8 / 5 (5) | 0 |
Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 ...
Immunology May 16, 2013 | not rated yet | 0
54 minutes ago | not rated yet | 0 |
1 hour ago | not rated yet | 1 |
18 hours ago | 4.2 / 5 (5) | 0 |
16 hours ago | 4.9 / 5 (14) | 0 |
18 hours ago | 4.6 / 5 (7) | 0 |
12 hours ago | 5 / 5 (5) | 0 |